MOSCOW (Reuters) – Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, the RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday.
The institute completed early-stage human trials, known as Phase II, earlier this month.
(Reporting by Maria Kiselyova; Writing by Alexander Marrow; Editing by Gareth Jones)
